SAFETY SUBGROUP ANALYSES FROM THE CECOG PHASE III TURANDOT TRIAL: FIRST-LINE BEVACIZUMAB (BEV) IN COMBINATION WITH CAPECITABINE (X) OR PACLITAXEL (P) FOR HER2-NEGATIVE LOCALLY RECURRENT OR METASTATIC BREAST CANCER (LR/MBC)

被引：0

作者：

Lang, I. ^{[1
]}

Inbar, M. ^{[2
]}

Greil, R. ^{[3
]}

Kahan, Z. ^{[4
]}

Beslija, S. ^{[5
]}

Steger, G. G. ^{[6
]}

Stemmer, S. M. ^{[7
]}

Zvribule, Z. ^{[8
]}

Kaufman, B. ^{[9
]}

Zielinski, C. ^{[10
,11
]}

机构：

[1] Natl Inst Oncol, Dept Med Oncol & Clin Pharmacol B, Budapest, Hungary

[2] Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, IL-69978 Tel Aviv, Israel

[3] Med Univ Salzburg, Dept Med, Salzburg, Austria

[4] Univ Med Sch Szeged, Szeged, Hungary

[5] Inst Oncol, Sarajevo, Bosnia & Herceg

[6] Med Univ Vienna, Med & Canc Ctr, Vienna, Austria

[7] Davidoff Ctr, Petah Tiqwa, Israel

[8] Riga Eastern Hosp, Latvian Ctr Oncol, Riga, Latvia

[9] Chaim Sheba Med Ctr, Div Oncol, Ramat Gan, Israel

[10] Univ Hosp, Dept Med 1, Vienna, Austria

[11] Ctr Canc, Vienna, Austria

来源：

ANNALS OF ONCOLOGY | 2010年 / 21卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：98 / 98

页数：1

共 50 条

[21] Efficacy and safety of first-line bevacizumab (Bev) combined with paclitaxel (Pac): An observational study in 786 patients (pts) with HER2-negative metastatic breast cancer (mBC). [J].

Klare, P. ;

Foerster, F. G. ;

Geberth, M. ;

Schneeweiss, A. ;

Tesch, H. ;

Kuemmel, S. ;

Schumacher, C. ;

Hollburg, W. ;

Soeling, U. ;

Schmidt, M. .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)

[22] First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients [J].

Miles, D. W. ;

Dieras, V. ;

Cortes, J. ;

Duenne, A. -A. ;

Yi, J. ;

O'Shaughnessy, J. .

ANNALS OF ONCOLOGY, 2013, 24 (11) :2773-2780

[23] A randomized, placebo-controlled phase II study of AMG 386 plus bevacizumab (Bev) and paclitaxel (P) or AMG 386 plus P as first-line therapy in patients (pts) with HER2-negative, locally recurrent or metastatic breast cancer (LR/MBC) [J].

Dieras, V. ;

Jassem, J. ;

Dirix, L. Y. ;

Guastalla, J. P. ;

Bono, P. ;

Hurvitz, S. A. ;

Goncalves, A. ;

Romieu, G. ;

Limentani, S. A. ;

Jerusalem, G. H. M. ;

Lakshmaiah, K. ;

Roche, H. H. ;

Sanchez-Rovira, P. ;

Pienkowski, T. ;

Segui-Palmer, M. A. ;

Li, A. ;

Sun, Y. ;

Pickett-Gies, C. A. ;

Wildiers, H. .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)

[24] Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer [J].

Vrdoljak, E. ;

Marschner, N. ;

Zielinski, C. ;

Gligorov, J. ;

Cortes, J. ;

Puglisi, F. ;

Aapro, M. ;

Fallowfield, L. ;

Fontana, A. ;

Inbar, M. ;

Kahan, Z. ;

Welt, A. ;

Levy, C. ;

Brain, E. ;

Pivot, X. ;

Putzu, C. ;

Gonzalez Martin, A. ;

de Ducla, S. ;

Easton, V. ;

von Minckwitz, G. .

ANNALS OF ONCOLOGY, 2016, 27 (11) :2046-2052

[25] Comparison of Subgroup Analyses of PFS from Three Phase III Studies of Bevacizumab in Combination with Chemotherapy in Patients with HER2-Negative Metastatic Breast Cancer (MBC). [J].

O'Shaughnessy, J. ;

Dieras, V ;

Glaspy, J. ;

Brufsky, A. ;

Miller, K. D. ;

Miles, D. W. ;

Koralewski, P. ;

Phan, S-C ;

Bhattacharya, S. .

CANCER RESEARCH, 2009, 69 (24) :512S-512S

[26] Exploratory analyses of candidate predictive and prognostic tissue biomarkers (BMs) in the open-label randomised phase III TANIA trial of bevacizumab (BEV) in HER2-negative locally recurrent/metastatic breast cancer (LR/mBC) [J].

Zielinski, C. ;

Gligorov, J. ;

Marschner, N. ;

Puglisi, F. ;

Vrdoljak, E. ;

Castan, J. Cortes ;

de Ducla, S. ;

Deurloo, R. ;

Easton, V. ;

von Minckwitz, G. .

ANNALS OF ONCOLOGY, 2016, 27

[27] PACLITAXEL (P) AND BEVACIZUMAB (BEV), AS FIRST-LINE CHEMOTHERAPY, IN PATIENTS WITH HER2-NEGATIVE METASTATIC BREAST CANCER (MBC). THE HELLENIC COOPERATIVE ONCOLOGY GROUP EXPERIENCE WITH BIOMARKER EVALUATION [J].

Kourea, H. P. ;

Koutras, A. K. ;

Kotoula, V. ;

Bobos, M. ;

Fountzila, A. Kalogera ;

Papazisis, K. T. ;

Christodoulou, C. ;

Res, E. ;

Bournakis, E. ;

Fountzilas, G. .

ANNALS OF ONCOLOGY, 2010, 21 :104-104

[28] Phase II study of bevacizumab (Bev) combined with weekly paclitaxel (wPac) as first-line therapy for Japanese patients (pts) with HER2-negative metastatic breast cancer (MBC). [J].

Masuda, N. ;

Aogi, K. ;

Ohno, S. ;

Iwata, H. ;

Kashiwaba, M. ;

Fujiwara, Y. ;

Ito, Y. ;

Ueno, T. ;

Saijo, N. ;

Takashima, S. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)

[29] Overall survival (OS) in the IMELDA randomized phase III trial of maintenance bevacizumab (BEV) with or without capecitabine (CAP) for HER2-negative metastatic breast cancer (mBC) [J].

Gligorov, Joseph ;

Bines, Jose ;

Alba, Emilio ;

Mustacchi, Giorgio ;

Cinieri, Saverio ;

Gupta, Vineet ;

Pierga, Jean-Yves ;

Bozcuk, Hakan ;

Gaafar, Rabab ;

Gupta, Sudeep ;

Vivanco, Guillermo Lopez ;

Wang, Xiaojia ;

Costa, Romulo ;

Altundag, Kadri ;

Chmielowska, Ewa ;

de Ducla, Sabine ;

Freudensprung, Ulrich ;

Cortes, Paulo ;

Doval, Dinesh .

CANCER RESEARCH, 2015, 75

[30] Real-world effectiveness and safety of first-line bevacizumab (BEV) plus paclitaxel (PAC) in > 2000 patients (pts) with HER2-negative metastatic breast cancer (mBC) [J].

Mueller, V. ;

Dank, M. ;

de Ducla, S. ;

Mitchell, L. ;

Schneeweiss, A. .

ANNALS OF ONCOLOGY, 2016, 27

← 1 2 3 4 5 →